Daunorubicin liposomal

Drug Profile

Daunorubicin liposomal

Alternative Names: Daunorubicin citrate liposome injection; DaunoXome; VS 103

Latest Information Update: 16 Nov 2012

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Gilead Sciences
  • Developer Galen Limited; Gilead Sciences; Swedish Orphan Biovitrum
  • Class Anthracyclines; Antineoplastics; Cytostatic antibiotics
  • Mechanism of Action Apoptosis stimulants; RNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity No

Highest Development Phases

  • Marketed Kaposi's sarcoma
  • Discontinued Acute myeloid leukaemia; Brain cancer; Breast cancer; Chronic lymphocytic leukaemia; Colorectal cancer; Lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma; Ovarian cancer; Precursor cell lymphoblastic leukaemia-lymphoma; Prostate cancer

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 15 Nov 2012 Daunorubicin liposomal receives orphan drug status for Acute myeloid leukaemia in European Union
  • 24 Feb 2012 Galen Ltd. acquires daunorubicin liposomal (DaunoXome®) from Gilead Sciences
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top